Changing Paradigm of Fatty Liver Management

Abstract

Metabolically-dysfunction-associated fatty liver disease is a major health concern globally and is on the rise worldwide. It is a form of chronic liver disease with potentials of progression to liver cirrhosis and hepatocellular carcinoma. For long, lifestyle modification remained the only effective intervention for the management of this disease. However, the scenario is now gradually changing. Not only newer drugs are showing promise in the management of metabolic dysfunction-associated fatty liver disease, but some have also already been approved by different regulatory bodies. These include semaglutide, resmetirom and saroglitazar. Therefore, a shift in the of paradigm of management of patients presenting to us with metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatohepatitis and complications is also gradually becoming visible.